S Mahner’s research while affiliated with Ludwig-Maximilians-Universität in Munich and other places

... In light of these results, the European Society of Gynaecological Oncology, the European Society for Medical Oncology, the European Society of Pathology (ESGO-ESMO-ESP), the American College of Obstetricians and Gynecologists, and the US Preventive Services Task Force (USPSTF) do not recommend routine OC screening for asymptomatic women with a baseline risk. This stems from concerns regarding the potential consequences of current screening approaches, such as invasive procedures following false-positive results [9,10,11,12]. ...

Reference:

Ovarian Cancer Screening: Recommendations and Future Prospects

... Despite the many differentially abundant proteins detected with stress sensitivity, only Actbl2 and Rhoa were significantly different in both tissues and sexes. Actbl2 and Rhoa both play a role in cytoskeletal organisation, stress fibres and focal adhesions, and are central for cellular migration [52][53][54][55][56]. Actbl2 is a novel actin isoform with 92% sequence homology to beta actin [57], and has been identified previously in striated muscle tissue [58]. ...

Reference:

Cardio-metabolic and cytoskeletal proteomic signatures differentiate stress hypersensitivity in dystrophin-deficient mdx mice

... Almahloul et al. (2023) Focaram no diagnóstico e tratamento da gravidez ovariana, destacando a importância da laparoscopia e técnicas minimamente invasivas, além de discutir fatores de risco específicos. Tremmel et al. (2024) Discutiram a mortalidade materna em gestações ectópicas não tubárias, analisaram fatores de risco, complicações graves, e compararam diferentes abordagens terapêuticas, incluindo histerectomia. Salari et al. (2020) Analisaram as complicações associadas ao tratamento com metotrexato, destacando os efeitos adversos e a importância de monitoramento contínuo. ...

Reference:

GESTAÇÃO ECTÓPICA: ABORDAGENS DIAGNÓSTICAS E TERAPÊUTICAS PARA UMA EMERGÊNCIA GINECOLÓGICA - UMA REVISÃO SISTEMÁTICA ATUAL

... The reported incidences of AFE range from 0.4 to 4.4 per 100,000 births in Europe [4]. Although the pathophysiology of AFE is not completely understood, disruption of maternal-fetal interface is thought to lead to abnormal activation of proinflammatory mediators and a cascade of deleterious events [5]. The clinical signs of AFE include collapse, respiratory distress, hypoxia, acute hypotension, cardiovascular arrest, disseminated intravascular coagulation (DIC), and neurological problems. ...

Reference:

Amniotic Fluid Embolism Coagulopathy Guided by the Point-of-Care Quantra QStat® Hemostasis System: A Case Report

... These centers offer comprehensive surgical expertise, thorough perioperative management, and appropriate adjuvant treatment options. Specialization and experience are considered to be quality indicators for beneficial clinical outcomes in primary and recurrent ovarian cancers [3,4]. ...

Reference:

Ovarian cancer management in an ESGO ovarian cancer center of excellence: a systematic case study of the interprofessional and interdisciplinary interaction

... Other developments have been reported in Germany, where telemedicine solution Trium CTG Mobile provided secure access to real-time fetal monitoring and maternal information from any location. More recently, Trium CTG Online integrated a smart Doppler device (HeraBEAT) to their 'mobile fleet' [132,133]. ...

Reference:

Advancements in Fetal Heart Rate Monitoring: A Report on Opportunities and Strategic Initiatives for Better Intrapartum Care

... The H1R receptor is highly expressed in many cancer cell lines and tumor tissues [139]. It is expressed in colorectal cancer [163][164][165], bladder cancer [166], ovarian cancer [167,168], breast cancer [169][170][171], liver cancer [68,172], pancreatic cancer [173], lung cancer [174], eye, head and neck cancer [146,172], brain cancer [175], blood cancer [176], skin cancer [109] and soft tissue cancer [154]. ...

Reference:

H1 Antihistamines—Promising Candidates for Repurposing in the Context of the Development of New Therapeutic Approaches to Cancer Treatment

... The 3-year overall survival for patients according Cancers 2023, 15, 1904 3 of 29 to cytoreduction status was 72.4% (complete resection), 65.8% (residual tumour ≤ 1 cm) and 45.2% (residual tumour > 1cm), respectively, in a combined analysis of three multicentre phase III trials (AGO-OVAR 3, 5, and 7) [14,23]. The goal of upfront cytoreduction should always be complete resection, especially in mucinous and clear-cell carcinoma where no benefit has been shown for residual disease ≤1 cm [14,[24][25][26]. However, small residual disease (i.e., ≤1 cm) may be acceptable in low-grade serous carcinoma, and possibly in tumours highly responsive to systemic treatment, such as high-grade serous tubo-ovarian carcinoma [26][27][28][29]. ...

Reference:

Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review

... The findings partially confirmed the GOG-0218 trial and might be potentially interesting in promoting personalized anti-VEGF treatment strategies. 28 Co-medication in Primary Ovarian Cancer Denschlag et al presented data from three phase III (AGO-OVAR 11/ ICON 7, 12, 16) and one phase II (AGO-OVAR 15) trials to assess the influence of metformin, statins, or beta-blockers on survival rates in patients with primary ovarian cancer. A total of 2857 patients were enrolled in the analysis and divided into comparable groups by the characteristics of "ever-user" (co-medication taken at least once during the trial) and "never-users" (control group). ...

Reference:

22nd meeting of the European Society of Gynaecological Oncology (ESGO 2021) report

... A tetravalent bi-specific antibody (istiratumab or MM-141) targeting both IGF1R and ErbB3 also markedly sensitized ovarian cancer cells to cisplatin and paclitaxel (Camblin et al. 2019) and pancreatic cancer xenograft models to gemcitabine and nab-paclitaxel treatments (Camblin et al. 2018) leading to subsequent human clinical trials in pancreatic cancer (Kundranda et al. 2020 fully humanized anti-IGF1R mAb from Amgen, is one of the latest and highly efficacious inhibitors of IGF1, IGF2 or insulin-mediated activation of IGF1R (Calzone et al. 2013). Ganitumab markedly potentiates the cytotoxic effects of carboplatin or paclitaxel in ovarian cancer (Beltran et al. 2014) of paclitaxel along with metformin in stage 2/3 breast cancer (Yee et al. 2021) and multiple others leading to a slew of human clinical trials of ganitumab in combination with different types of chemotherapy in breast cancer (Robertson et al. 2013), ovarian cancer (Konecny et al. 2021), advanced solid tumors (Murakami et al. 2012, Rosen et al. 2012, metastatic pancreatic cancer (Kindler et al. 2012, Okusaka et al. 2014, Fuchs et al. 2015, extensive-stage small-cell lung cancer (Glisson et al. 2017) and metastatic colorectal cancer (Cohn et al. 2013). In fact, ganitumab has been approved by the US Food and Drug Administration as an orphan drug for Ewing sarcoma in 2017. ...

Reference:

GH and IGF1 in cancer therapy resistance